Bifogade filer
AroCell Interim Report Q2 2023
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
A word from the CEO
”The positive sales development continued in the second quarter, with steady growth in our two main segments, bacteriology and oncology. AroCell remains strong with a solid cash position and stable and robust sales growth. We have a highly skilled organization that covers all aspects of our operations, from research and development to sales, production, and distribution. We are diligently following our five-point strategy and are beginning to see the benefits of our emphasis on rapid testing and CLIA platforms. With a clear strategy and a dedicated team, we have all the necessary prerequisites to achieve success.”
Anders Hultman, CEO
Reporting period April 1st – June 30th
- Net sales amounted to KSEK 11,775 (6,349).
- Profit after financial items amounted to KSEK -15,490 (-16,016)*.
- Cash flow from operating activities for the period amounted to KSEK -2,342 (-1,397).
- Earnings per share before and after dilution amounted to SEK -0.07 (-0.07).
- Cash and cash equivalents at the end of the period amounted to KSEK 57,548 (69,814).
* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.
Reporting period January 1st – June 30th
- Net sales amounted to KSEK 22,828 (14,118).
- Profit after financial items amounted to KSEK -29,158 (-31,710)*.
- Cash flow from operating activities for the period amounted to KSEK -6,864 (-9,517).
- Earnings per share before and after dilution amounted to SEK -0.13 (-0.16).
- Cash and cash equivalents at the end of the period amounted to KSEK 57,548 (69,814).
* Includes costs for goodwill amortization of KSEK 19,789 (19,789) for the period.
Events during the period April 1st – June 30th
- AroCell held its annual general meeting on 24 May 2023.
- TPS CLIA was approved for use on Fosun Diagnostics fully automated CLIA platforms in China. TPS CLIA is already approved on ZENCEN Biotech’s CLIA platform and was launched earlier this year.
Events after the period
- AroCell has signed an additional agreement with ZECEN Biotech for the development of its third tumor marker product, TK 210 ELISA, on ZECEN Biotech’s automated platforms. This collaboration is an important milestone for AroCell as the company strives to expand its product range and improve cancer diagnostics.
Interim report January 1st – June 30th, 2023 (Link)